Table 1

Demographic and baseline characteristics

Liraglutide 1.8 mgPlacebo
(n = 140)(n = 137)
Sex, n (%)
 Female65 (46.4)72 (52.6)
 Male75 (53.6)65 (47.4)
Age, mean (SD), years68.0 (8.3)66.3 (8.0)
Age-group, n (%)
 18–64 years38 (27.1)55 (40.1)
 65–74 years72 (51.4)66 (48.2)
 >75 years30 (21.4)16 (11.7)
Duration of diabetes, mean (SD), years15.9 (8.9)14.2 (7.5)
Race, n (%)
 White123 (87.9)129 (94.2)
 Black or African American14 (10.0)4 (2.9)
 Asian non-Indian2 (1.4)1 (0.7)
 Asian Indian1 (0.7)0
 Native Hawaiian or other Pacific Islander01 (0.7)
 Other02 (1.5)
Insulin treatment, n (%)
 Basal29 (20.7)24 (17.5)
 Premix48 (34.3)52 (38.0)
 No insulin63 (45.0)61 (44.5)
Total daily insulin dose, geometric mean (CV), IU47.1 (0.70)50.8 (0.85)
Oral glucose-lowering therapies, n (%)
 Metformin14 (10.0)12 (8.8)
 SU15 (10.7)19 (13.9)
 Pioglitazone1 (0.7)1 (0.7)
 Metformin + SU26 (18.6)25 (18.2)
 Repaglinide*1 (0.7)0 (0.0)
 Metformin + pioglitazone1 (0.7)1 (0.7)
 SU + pioglitazone1 (0.7)1 (0.7)
 MET + SU fixed combination*1 (0.7)1 (0.7)
 Metformin + SU + pioglitazone1 (0.7)0 (0.0)
 Metformin + SU + acarbose*1 (0.7)0 (0.0)
HbA1c, mean (SD), % 8.08 (0.792)8.00 (0.853)
HbA1c, mean (SD), mmol/mol 64.8 (8.66)63.9 (9.33)
FPG, mean (SD), mmol/L9.48 (3.270)9.27 (2.842)
FPG, mean (SD), mg/dL 170.83 (58.92)167.03 (51.21)
Body weight, mean (SD), kg 93.63 (17.41)95.63 (17.65)
BMI, mean (SD), kg/m233.4 (5.4)34.5 (5.4)
eGFR, geometric mean (CV), mL/min/1.73 m2 45.4 (0.23)45.5 (0.25)
eGFR, mL/min/1.73 m2, n (%)
 30 to <4561 (43.6)59 (43.1)
 45–5978 (55.7)78 (56.9)
 >591 (0.7)0 (0.0)
UACR, geometric mean (CV), mg/g55.5 (7.58)69.8 (5.75)
Blood pressure, mean (SD), mmHg
 Systolic135.2 (14.8)136.8 (14.4)
 Diastolic77.2 (9.8)78.1 (9.3)
Hypertension, % patients at screening90.088.3
  • CV, coefficient of variance.

  • *Combination of background medication not allowed according to the protocol.